There is debate in Australia and New Zealand around the appropriate use of illness severity scoring systems in Australasian intensive care units. The international benchmark is the Acute Physiological and Chronic Health Evaluation (APACHE) system. In order to compare the performance of recent APACHE releases, we audited 2080 sequential patients admitted between 1 January 2006 and 31 March 2008 to the Middlemore Hospital intensive care unit in Auckland, New Zealand. We compared the predictive performance of the proprietary APACHE II, IIIh, IIIj and IV releases, and the performance of a 'localised' version of APACHE II containing re-estimated coefficients derived from a legacy dataset (7703 sequential patients admitted between 1 January 1997 and 31 December 2005). Discrimination assessed by receiver operating characteristic curves was highest with the APACHE III and IV releases, and significantly better than the APACHE II releases. Calibration assessed by the Hosmer-Lemeshow statistic was poor with all releases, although it was best with APACHE IV and 'localised' version of the APACHE II release. Overall accuracy assessed by the Brier Mean Probability score and Shapiro's R statistic was best with APACHE IV. Our study suggests the possibility of improved prediction in moving to APACHE IV from older releases, although broader multicentre study within the Australian and New Zealand critical care community is warranted. Our study also suggests that localisation of the APACHE system offers further opportunity to improve prediction, although these improvements may not be major without ground-up development of a new risk prediction model within our local critical care setting.
Illness severity scoring systems have become indispensable tools of intensive care medicine. Their origin in the late 1970s and early 1980s was driven by the need to relate intensive care practice patterns to patient outcomes. In the modern setting, such tools allow researchers and clinicians to quantify patient illness severity with a greater degree of accuracy and precision. This can be used to account for patient casemix which is crucial when evaluating outcomes, both within and between intensive care units.
The international benchmark for scoring illness severity is the Acute Physiological and Chronic Health Evaluation (APACHE) system, which was originally developed by Knaus and colleagues 1 . This original system has undergone serial enhancements as proprietary products, such that there are now three more major releases of the original system in use: APACHE II, APACHE IIIh/IIIi/IIIj and APACHE IV [2] [3] [4] . In the New Zealand setting (as elsewhere), it is clear that the performance of the APACHE II scoring system has deteriorated over the 20 years or more since its release 5 . Patient casemix has changed, and improvements in supportive care may have decreased mortality for any given illness severity and diagnostic category. Both international and local opinion leaders have moved to the more recently developed APACHE releases which have been shown to outperform their older counterparts in studies of North American, European and Australasian intensive care unit (ICU) populations 6 . The most recent APACHE IV release is currently being promoted by the developers as the most accurate in terms of both discrimination and calibration 7 . Currently, the Australian and New Zealand Intensive Care Society Adult Patient Database collects data sufficient to model APACHE IIIj scores in addition to older models 8 .
In this report, we compare the performance of all of the recent APACHE releases for the prediction of mortality from illness severity using data from a single New Zealand ICU from 2005 to 2008. In addition to the proprietary APACHE systems, we also make comparisons to a 'localised' version of the APACHE II release with recalculated diagnostic category weightings to better account for our patient population and treating hospital characteristics.
MATERIALS AND METHODS

Study design
Our study is a retrospective analysis of a nonrandomised observational cohort.
Study setting and participants
The setting for our study was Middlemore Hospital, the main hospital within the Counties Manukau District Health Board catchment in South Auckland, New Zealand. Counties Manukau District Health Board serves one of the largest urban populations in New Zealand. The population can be summarily characterised as being young, multi-ethnic and of low socio-economic status when compared with the rest of New Zealand 9 . Middlemore Hospital is a 900-bed tertiary referral centre for plastic surgery, orthopaedics and a range of medical subspecialities. The hospital does not perform coronary artery bypass grafting or other cardiac surgery, or neurosurgery. The Middlemore Hospital ICU is best described as a mixed ICU, and is currently an 18-funded bed Level 3 facility 10 .
The main cohort for our study (the validation/ testing cohort) comprised consecutive patients admitted to the Middlemore Hospital ICU between the dates of January 2006 and March 2008. We excluded patients from the study if they were <16 years of age, or admitted with burns or after transplant operations. Patients who were admitted solely for the purpose of a procedure such as difficult central venous line or endoscopy do not receive an illness severity score in our ICU and we excluded these patients as well. Of note, we excluded patients who were transferred from another ICU during the same hospitalisation, and only analysed a patient's first ICU admission if readmitted to ICU during the same hospitalisation. This is a standard approach and avoids counting more than one hospital outcome for the same patient.
A separate cohort (the determination/training cohort) was used for recalibration of the APACHE II release into a 'localised' version, comprising consecutive patients admitted to the Middlemore Hospital ICU between the dates of January 1997 and December 2005. This cohort has been described elsewhere 5 . We applied the same exclusion criteria as for the study cohort.
Data source
The validation/testing dataset for our study was sourced from a single-centre MS Access-based database. Our procedures for data collection and methods for ensuring accuracy have been described previously 5 . The outcome of hospital mortality in the database for every patient was checked against hospital clinical records to eliminate possible misclassification. The determination/training dataset for the recalibration of the APACHE II release was sourced though a legacy dataset that has also been described previously 5 . This legacy dataset contains only patient demographics, their composite APACHE II score and APACHE diagnostic code, source of admission and patient hospital outcome. The dataset does not contain component chronic health or acute physiology domain data.
Calculation of APACHE scores and risk of death
We calculated APACHE II, III and IV scores and risk of death at patient hospital discharge using the proprietary logistic regression equations provided to us by the developers. All APACHE scores encompass acute physiological status, age and chronic health status, and risk of death is calculated from raw scores and diagnostic categories. For APACHE III, there are three versions (IIIh, IIIi, IIIj) that have been released, the first in 1991 and the last in 2001 3, 11 . The APACHE IIIi and IIIj versions differ from the original due to modelling of the Acute Physiology Score (APS) as a splined variable and an increase in the number of disease categories from 78 to 94. The final APACHE III release (IIIj) differs from all the earlier versions due to modelling of both the APS and age as splined variables, as well as the use of a variable that re-scales P a O 2 /FiO 2 in the APS 7, 11 . In this research, we calculated APACHE III scores and risk of death using the original (IIIh) and final (IIIj) versions.
We also calculated APACHE II risk of death using the 'localised' version of the release. This was done by re-estimating the coefficients for the APACHE II score, the diagnostic category and the emergency surgery category using logistic regression, leaving the composite APACHE II score in status quo. Of note, there was no re-estimation of component variables within the APS, age, or medical history. This method is consistent with those used to originally recalibrate and subsequently update the APACHE II (UK) model [12] [13] [14] [15] . It is different, however, from those used to develop entirely new risk prediction models such as the Intensive Care National Audit and Research Centre (ICNARC) risk prediction model 16, 17 . In the ICNARC model, for instance, researchers used novel approaches to the modelling of physiological parameters and included interactions terms between diagnostic categories and physiological scores. In contrast, the 'localisation' of the APACHE II risk of death in our study is a mere recalibration rather than a wholesale re-development of a new model, and our approach corresponds to one of several that are recommended for this task in the literature 15 . Given the availability of the independent validation/testing dataset, the re-estimation of coefficients was performed using the entire determination/training dataset 18 . Because of this and also the single centre nature of our data, no re-sampling of data was necessary for model recalibration: this is only required when splitting the same dataset for both validation/testing and determination/training, especially when allocation is performed using ICUs in a multi-centre dataset 15 .
Statistical methods
All analyses were performed in Microsoft Excel (Microsoft Corporation, Seattle, WA, USA) and Intercooled Stata/MP 11.1 (Statacorp, College Station, TX, USA). We used standard statistics to describe data, making particular use of median and interquartile range to avoid assumptions around data distribution. We undertook hypothesis testing using Kruskal-Wallis equality-of-populations rank test for continuous variables, and the Pearson's chi-squared test for categorical ones.
We gauged the overall predictive performance of the APACHE releases through discrimination (ability to discriminate between the patients who will die or survive at hospital discharge) and calibration (ability to predict mortality rate over classes of risk). We assessed discrimination using receiver operating characteristic (ROC) curves using the roctab and rocfit commands in Stata, which plot the true positive rate (sensitivity, or predicted hospital deaths/observed hospital deaths) against the false positive rate (1-specificity, or 1-predicted hospital deaths/observed hospital deaths) 19, 20 . The predictive performance is indicated in this method by the c-statistic, which is the probability that a randomly chosen non-survivor will have a higher predicted probability of death that a randomly chosen survivor. This statistic is identical to the area under the ROC curve (AUROC), with a value of 0.5 equating to random prediction and a value of 1.0 equating to perfect discrimination. The slope the curve indicates ratio of true positives and false positives, also known as the likelihood ratio. We compared the equality of AUROC between the APACHE releases using an algorithm suggested by DeLong et al, implemented using the roccomp command in Stata 21 .
We assessed calibration using the correspondence between the number of observed hospital deaths and the number of predicted hospital deaths within 10 equal-sized groups based on quantiles of predicted mortality. This quantile-type grouping method was chosen over one based on fixed cut points of risk, due to better adherence the χ 2 distribution 22, 23 . The predictive performance is indicated in this method by goodness-of-fit as assessed by the Hosmer-Lemeshow statistic 24 . In this study, a high χ 2 value for deciles of risk (>15.5, df=8) and a low P value (<0.05) indicates lack of satisfactory model fit.
Finally, we assessed overall model accuracy (reflecting both discrimination and calibration) using two statistics of a suite recommended by the ICNARC investigators [15] [16] [17] 25, 26 : the Brier Mean Probability score (mean square error between prediction and outcomes) and its derivatives [27] [28] [29] , and Shapiro's R (geometric mean probability assigned to the outcomes that occurred) 30 . Full details of these statistics and their rationale have been presented in a number of publications by the ICNARC investigators, and only a brief outline is provided here. These statistics are advocated as they are "strictly proper" scoring rules, providing a quantitative assessment of the quality of fit for models with binary outcomes 31 . Such assessment is not a feature of error-rate methods or the sensitivity/ specificity methods that are derived from them (e.g. ROC curves). Error-rate methods do not take into account the magnitude of prediction error. For instance, they will assign the same prediction for a given patient whether their computed probability of death is marginally more than 0.5 or whether it is almost 1.0 26 . In contrast, the Brier Mean Probability score and its derivatives are optimised only when the predicted probability of death from the risk prediction model equals the actual probability. For perfect prediction, the Brier Mean Probability score is minimised (that is, zero). For poor prediction, when a probability of 0.5 is assigned to every patient, the Brier Mean Probability score is 0.25. Shapiro's R has similar properties as a "strictly proper" scoring rule, and is derived from Shapiro's Q (specifically, R=2 (Q-1) ) (D. A. Harrison, personal communication). For perfect prediction, Shapiro's R is maximised (that is, 1.0). For poor prediction, when a probability of 0.5 is assigned to every patient, Shapiro's R is 0.5. Both the Brier Mean Probability score and Shapiro's R are bounded between 0 and 1, and penalise mispredictions that are worse than predicting a constant of 0.5 for all patients.
The need for formal ethics approval for the research process was waived by the National (New Zealand) Health and Disability Ethics Committee under the provisions made for clinical audit.
RESULTS
A total of 2080 and 7703 patients were included in the validation and determination datasets. Baseline characteristics of these cohorts are described in Table 1 . Of note, there have been changes in the casemix of patients, with an increase in the number of patients admitted after elective or emergency surgery, and an increase in those admitted with a gastrointestinal diagnosis. The proportion of patients requiring mechanical ventilation has progressively reduced. Overall hospital mortality has decreased.
The recalculated coefficients for diagnostic category that we used for the 'localised' APACHE II version are provided in Table 2 . The absoulte values of these coefficients cannot be compared directly to those of the proprietary APACHE II release since the reference categories in the two versions are different. However, there is significant correlation between the 'localised' and proprietary APACHE II coefficients (P value 0.0098), indicating a similar statistical effect of diagnostic category on the relationship between outcomes and physiological scores in each of the APACHE II versions (Figure 1 ).
The performance of the different models for discrimination is shown in Table 3 and illustrated in Figures 2 and 3 . In general, there is generally better performance with later APACHE releases with c-statistics and AUROCs approaching 0.8 for the APACHE III and IV predictions. This represents the well described phenomenon of 'model fade' in the older releases. Of note, the overall accuracy of the 'localised' APACHE II version was better than the proprietary APACHE II one, while the discrimination of the APACHE III and IV releases were statistically and clinically indistinguishable.
The performance of the different models in terms of calibration is shown in Table 3 and illustrated in Figure 4 . There is better goodness-of-fit with the 'localised' APACHE II and APACHE IV releases, although there remained statistically significant differences between the predicted and observed mortality with all models. For the most part, all APACHE releases overestimated mortality risk. The exception is for patients with the lowest decile of risk. Given the log scales of Figure 4 , the difference in between predicted and observed mortality rate in this group is small: the expected number of deaths in this category was 3.48, and the observed number of deaths was seven. A chart review of these seven cases showed that three of these patients died of complications following carotid endarterectomy surgery, and two died of cardiac arrests in the context of overdoses with proarrhythmic medication.
Overall model accuracy is shown in Table 3 . Considering discrimination, calibration, and overall model accuracy, the APACHE IV release was the best performing model with the 'localised' APACHE II version next. The APACHE IV release was most accurate in the diagnostic groups belonging to the musculoskeletal/skin systems, and least accurate in those belonging to the respiratory system ( Figure 5 ).
DISCUSSION
The use of illness-severity adjusted mortality rates is essential for benchmarking and the implementation of quality initiatives in the ICU. Such activities are increasingly a routine part of clinical practice in ICUs. In Australia and New Zealand, the College of Intensive Care Medicine requires as a minimum standard that all ICUs have documented and demonstrable procedures for formal audit, peer review and quality assurance 32 . As such, the accuracy of illness severity scoring systems is an important element of clinical care.
Our results show that the last release of the APACHE scoring system had the best performance in our cohort, although the differences between the APACHE IV and APACHE IIIj releases were minimal. Discrimination was best with the APACHE IV and APACHE IIIj releases, both of which outperformed older ones. Calibration best with the APACHE IV and localised version of the APACHE II release, although we acknowledge the limitations of Hosmer-Lemeshow statistic in small cohorts 33 . Overall accuracy was best with the APACHE IV release, with an incremental improvement of 2 to 4% over previous APACHE releases. This degree of improvement is similar to that seen in the original validation studies for the ICNARC risk prediction model, which has now replaced previous models for risk adjustment in the UK. Ultimately, the clinical value of a 3 to 4% improvement in accuracy is an issue that will require debate and consensus within the entire Australian and New Zealand critical care community. Notwithstanding, our study suggests the possibility of improved prediction in moving to APACHE IV from older releases, and broader multicentre study within Australia and New Zealand.
The performance of the all APACHE releases was lower than expected in our cohort. Our results can be compared with those reported using a cohort of 223,129 patients from 1993 to 2003 from the Australian and New Zealand Intensive Care Society Adult Patient Database. In that study, the AUROCs were 0.85 and 0.87 for the APACHE II and IIIj releases, respectively 34 . Even given the discrepancy in era, our results show a lower predictive performance. This situation could arise for a number of reasons, including poor data collection. More plausibly, it could also arise from unmeasured confounding as a Localised APACHE II   APACHE II  tabLe 3 Model discrimination, calibration, and overall adequacy by APACHE release result of local differences in processes or quality of care and local differences in patient characteristics. Such differences are probably responsible for the systematically lower performance of predictive models in individual ICUs when they have been developed within larger national or regional populations 35 . In our study, differences in demographics between our cohort and those of North America are notable, as they have been in other similar studies [36] [37] [38] [39] . One particular difference in our cohort is the high proportion of Pacific people, which reflects the source population within the Counties Manukau District Health Board. It is plausible that this ethnicity and its related characteristics are associated with better outcomes. For example, there is a positive association between body mass index and survival in critically ill patients 40, 41 . Obesity affects 32.3% of our source population, reflected in the typical body mass index of the patients in our study. Factors such as these within any specific population are well known to reduce the performance of illness severity scoring systems that are developed elsewhere.
Our study suggests a role for recalibration of the APACHE system within the Australian and New Zealand critical care community, in order to 'localise' the system to patient populations and treating hospital characteristics. In general, this approach does result in better prediction within the time-periods and settings in which the models are calibrated, but makes models less generalisable and valid for widespread benchmarking 42 . In our study, the improved accuracy with the 'localised' APACHE II version is similar to or better than that reported by the ICNARC investigators 15 . However, the greater improvements in the performance of illness severity scoring systems over the years have not occurred from merely updating or re-calculating regression coefficients, but instead have required the application of new statistical methods, the introduction of new variables, and changes in the measurement of old ones in order to generate entirely new risk prediction models 11, 25 . Notwithstanding, 'localisation' could be done in a less drastic fashion in the first instance, such as re-estimating the coefficients for the diagnostic category and emergency surgery, or by introducing other variables that more usefully capture local patient characteristics and practice patterns. This could be done for Australia and New Zealand as a whole, introducing variables into the prediction model such as ICU level and locality (rural, urban) that are locally relevant and ubiquitous.
The limitations of our study relate to the single centre nature of the research giving rise to the external validity problems as discussed above, and the small number of patients in the validation dataset giving rise to the possibility of type II error. However, the study does accurately reflect the realities of illness severity scoring systems for benchmarking and quality purposes in individual hospitals such as ours. For this purpose, the APACHE release of choice is that which best predicts hospital death in the local setting. The strengths of our study include the use of all of APACHE releases in modelling, including the use of a 'localised' version.
In summary, the performance of all of the APACHE releases in our hospital is less than that described in the original publications. Overall, the APACHE IV release provides more accurate prediction compared to the older releases. 'Localisation' of the APACHE system is likely to offer an opportunity for further improvement, although our study and those of others suggest that these improvements may not be dramatic without ground-up development of a new risk prediction model within the Australian and New Zealand critical care setting.
